4563: AnGes, Inc. - Summary | Jitta

AnGes, Inc.

TYO:4563

Price
¥50.00
Loss Chance
54.1%
2.60JITTA SCORE
100.00%Over Jitta Line
Jitta Ranking
100 / 184
2,255 / 3,513
Grow your money with Jitta Ranking. See details.
HISTORICAL JITTA SCORE
Jitta Factors
Growth Opportunity (66)
Recent Business Performance (64)
Financial Strength (37)
Return to Shareholders (0)
Competitive Advantage (49)
Jitta Signs
Recent Business PerformanceEarning Growth Last Year
SG&A to SalesDecreasing Every Year
Revenue and EarningEarning loss detected in 2025
New Share IssuedMore than 50% in 5 years
CapExVery High
Cash Conversion CycleMore than 1 year
Key Stats
Jitta Score
Jitta Line
2.60
100.00%
2.16
172.04%
4.36
368.05%
Biotechnology
3.32
100.00%
2.10
> 1,000%
2.52
100.00%
COMPANY DESCRIPTION
AnGes, Inc. engages in the research and development of gene-based medicines. It develops HGF gene therapy product for the treatment of chronic arterial occlusive disease; NF-KB decoy oligonucleotide for chronic discogenic lumbar back pain; and DNA vaccines for the treatment of hypertension, as well as tie2 agonists for COVID-19/ARDS and drugs for chronic hepatitis B. AnGes, Inc. was formerly known as AnGes MG, Inc. and changed its name to AnGes, Inc. in July 2017. The company was incorporated in 1999 and is headquartered in Ibaraki, Japan.